By Phase III, researchers are supposed to have a pretty good handle on just how promising an experimental therapy can be. There's proof-of-concept data in the can and some clear indications of just how big a market a new drug can go on to capture.
But even if the odds of success are somewhat better, the risk for losing big is greater as well. A pharma company often steps in to nail down a licensing deal, but late-stage trials typically require large patient populations and consume enormous budgets.
To read the full, original article click on this link: The Top 10 Phase III Failures of 2010 - FierceBiotech
Author: John Carroll
